Johnson & Johnson (NYSE:JNJ) Shares Bought by Drive Wealth Management LLC

Drive Wealth Management LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 1.7% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 10,081 shares of the company’s stock after acquiring an additional 168 shares during the period. Drive Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,634,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. First Western Trust Bank grew its stake in shares of Johnson & Johnson by 1.1% during the 3rd quarter. First Western Trust Bank now owns 19,636 shares of the company’s stock valued at $3,182,000 after buying an additional 214 shares during the period. Strengthening Families & Communities LLC grew its position in Johnson & Johnson by 8.2% during the third quarter. Strengthening Families & Communities LLC now owns 20,361 shares of the company’s stock valued at $3,300,000 after acquiring an additional 1,547 shares during the period. Holistic Financial Partners raised its holdings in shares of Johnson & Johnson by 3.6% in the 3rd quarter. Holistic Financial Partners now owns 3,598 shares of the company’s stock worth $583,000 after purchasing an additional 125 shares during the period. Richard C. Young & CO. LTD. lifted its stake in shares of Johnson & Johnson by 1.7% in the 3rd quarter. Richard C. Young & CO. LTD. now owns 74,216 shares of the company’s stock valued at $12,027,000 after purchasing an additional 1,237 shares in the last quarter. Finally, Equity Investment Corp grew its holdings in shares of Johnson & Johnson by 1.2% during the 3rd quarter. Equity Investment Corp now owns 86,613 shares of the company’s stock worth $14,036,000 after purchasing an additional 1,004 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares in the company, valued at approximately $3,131,683.38. This trade represents a 22.90 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on JNJ shares. Wolfe Research initiated coverage on shares of Johnson & Johnson in a research report on Friday. They issued an “outperform” rating and a $190.00 price objective for the company. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Wells Fargo & Company raised their target price on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Finally, Guggenheim lifted their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Seven investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $175.94.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $154.00 on Monday. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $168.85. The company has a market cap of $370.77 billion, a PE ratio of 22.29, a P/E/G ratio of 2.74 and a beta of 0.53. The stock has a 50 day simple moving average of $161.35 and a 200-day simple moving average of $156.13. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm’s quarterly revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.66 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 9.93 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.22%. Johnson & Johnson’s payout ratio is 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.